CUSIP: 54142F102
Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
12,621,946
-
Share change
-
+12,621,946
-
Total reported value
-
$131,266,000
-
Price per share
-
$10.40
-
Number of holders
-
36
-
Value change
-
+$131,265,997
-
Number of buys
-
36
Quarterly Holders Quick Answers
What is CUSIP 54142F102?
CUSIP 54142F102 identifies LOGC - LOGICBIO THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 54142F102:
Institutional Holders of LOGICBIO THERAPEUTICS INC - COM (LOGC) as of Q4 2018
As of 31 Dec 2018,
LOGICBIO THERAPEUTICS INC - COM (LOGC) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,621,946 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Redmile Group, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Board of Trustees of The Leland Stanford Junior University, FRANKLIN RESOURCES INC, SAMLYN CAPITAL, LLC, Lion Point Capital, LP, SPHERA FUNDS MANAGEMENT LTD., BlackRock Inc., and Vanguard Group Inc.
This page lists
36
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.